Who Owns Knight Company?

Knight Bundle

Get Full Bundle:

	BCG	$15	$10
	5 FORCES	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Knight Therapeutics?

Understanding Knight Therapeutics' ownership is key for investors. Its public debut in 2014 followed the acquisition of Paladin Labs Inc. by Endo International, distributing Knight shares to Paladin shareholders.

Founded in November 2013, Knight Therapeutics is a specialty pharmaceutical firm focused on the Americas (excluding the U.S.). It aims to acquire, develop, and commercialize a range of prescription drugs and biosimilars.

Who owns Knight Therapeutics Inc.?

Knight Therapeutics Inc. is a significant specialty pharmaceutical company with a market capitalization of CAD 612.87 million as of July 25, 2025. In 2024, the company achieved revenues of $371.3 million, a 13% increase year-over-year. For fiscal year 2025, it projects revenues between $390 million and $405 million. The company's portfolio includes treatments like Knight BCG Matrix, contributing to its financial performance and market position.

Knight Therapeutics Inc. was established in November 2013 as a wholly owned subsidiary of Paladin Labs Inc. The company's public debut on February 28, 2014, was a direct consequence of Endo International's acquisition of its parent entity, Paladin Labs Inc.

Founding Structure

Knight Therapeutics was initially formed as a subsidiary of Paladin Labs Inc. Its public listing was facilitated by Paladin's acquisition by Endo International.

Initial Ownership Distribution

Following the acquisition of Paladin Labs Inc., existing Paladin shareholders received shares in the newly formed Knight Therapeutics. This effectively distributed the initial ownership among a broad group of former Paladin investors.

Key Founder Involvement

Jonathan Ross Goodman, a co-founder and former CEO of Paladin Labs Inc., played a crucial role in the predecessor company and remains a significant figure in Knight Therapeutics.

Management Transition

Samira Sakhia, who previously served as CFO at Paladin Labs Inc., joined Knight Therapeutics in a leadership capacity. Her experience in executing strategic transactions likely shaped Knight's early direction.

Early Corporate Structure

While specific early agreements are not publicly detailed, the spin-off structure from Paladin Labs Inc. aimed to establish Knight as an independent public entity.

Public Listing

Knight Therapeutics became a publicly traded company on February 28, 2014. This transition was a direct result of the acquisition of its parent company, Paladin Labs Inc.

The ownership of Knight Company is primarily distributed among its public shareholders following its initial public offering. While specific details regarding early equity splits at its inception are not publicly disclosed, the company's transition to a public entity in February 2014 was a direct outcome of its parent company's acquisition. This event led to the distribution of Knight's initial ownership among the former shareholders of its parent. Key figures from the predecessor company, such as Jonathan Ross Goodman, who was instrumental in its founding, continue to hold significant influence. Similarly, Samira Sakhia's extensive financial background from her tenure at the predecessor company has been vital to Knight's strategic development and execution of key transactions. Understanding the Mission, Vision & Core Values of Knight can provide further context into the company's direction and how its ownership structure influences its operations.

Knight Company Ownership Overview

Knight Company's ownership structure evolved significantly with its public listing in 2014. The initial ownership was a result of a corporate transaction involving its parent company.

• Knight Therapeutics Inc. was founded in November 2013.
• It began as a wholly owned subsidiary of Paladin Labs Inc.
• The company became publicly traded on February 28, 2014.
• This public listing occurred after Paladin Labs Inc. was acquired by Endo International.
• Existing Paladin shareholders received shares of Knight Therapeutics, forming its initial ownership base.
• Jonathan Ross Goodman, a co-founder of Paladin Labs Inc., played a foundational role.
• Samira Sakhia, formerly CFO of Paladin Labs Inc., has held key executive positions at Knight Therapeutics.

Knight SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Knight Therapeutics Inc. transitioned to a public entity on February 28, 2014, listed on the Toronto Stock Exchange under the ticker 'GUD'. The acquisition of a controlling interest in Grupo Biotoscana in November 2019, finalized by August 2020, marked a significant shift, expanding its presence into Latin America and influencing its market standing and strategic direction.

As of July 25, 2025, Knight Therapeutics Inc. held a market capitalization of CAD 612.87 million, representing a 5.01% increase year-over-year. The company has authorized an unlimited number of common shares, with 99,540,084 common shares issued and outstanding as of March 19, 2025. This structure indicates a publicly traded entity with a broad shareholder base, including significant institutional investors and key individuals within its management and founding circles. The company's performance has been bolstered by strategic acquisitions, such as the full integration of Grupo Biotoscana, which has contributed to consistent revenue growth and an increase in adjusted EBITDA since 2019.

Key Ownership Details

Understanding Knight Company ownership involves examining both institutional and insider holdings. The company's public trading status means no single owner controls the entirety of its decisions.

• Knight Therapeutics Inc. is publicly traded on the TSX under the symbol 'GUD'.
• Major institutional investors collectively held over 4 million shares as of May 30, 2025.
• Jonathan Ross Goodman, a key insider, holds a substantial number of shares both directly and indirectly.
• The company's ownership structure has evolved through strategic acquisitions, impacting its market position.
• For a deeper dive into the competitive landscape, explore the Competitors Landscape of Knight.

Knight PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors for Knight Therapeutics Inc. is comprised of seven individuals elected to guide the company's strategic direction. As of the May 7, 2025, Annual General Meeting, the board includes Jonathan Ross Goodman, James C. Gale, Samira Sakhia, Robert N. Lande, Michael J. Tremblay, Nicolás Sujoy, and Janice Murray. Jonathan Ross Goodman holds a significant stake in the company, both directly and indirectly, making him a key figure in Knight Company ownership.

Knight Therapeutics operates under a straightforward voting structure where each common share carries one vote. As of March 19, 2025, the company had 99,540,084 common shares issued and outstanding. This structure implies that Knight Company ownership is directly proportional to the number of shares held, with no indications of preferential voting rights or dual-class share systems that would alter this balance. While past shareholder activism has occurred, such as the 2019 dispute involving a 7.3% stake, current filings do not highlight recent governance challenges or proxy battles, suggesting a stable management structure. Understanding this structure is key to grasping Who owns Knight Company and how decisions are made.

Understanding Knight Company's Voting Power

The voting power within Knight Therapeutics is directly tied to share ownership, with each common share granting one vote. This ensures a transparent and equitable distribution of influence among shareholders.

• One-share-one-vote system for common shares.
• 99,540,084 common shares outstanding as of March 19, 2025.
• No evidence of dual-class shares or special voting rights.
• Shareholder decisions are based on proportional ownership.
• This structure influences Knight Company's decision-making process.

For a deeper dive into the company's journey, explore the Brief History of Knight.

Knight Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, Knight Therapeutics Inc. has been actively shaping its ownership landscape through strategic share repurchases and significant acquisitions. These actions reflect a clear intent to enhance shareholder value and expand its market presence, particularly in Canada.

Knight Therapeutics has demonstrated a consistent strategy of returning capital to shareholders through share buybacks, evidenced by its 5-year share buyback ratio of 6.40% as of March 2025. Concurrently, the company has pursued significant acquisitions to bolster its portfolio and market position. The acquisition of the Paladin business, finalized in June 2025, and the deal with Sumitomo for Canadian assets, announced in June 2025, are key examples of this strategy. These moves are intended to increase the company's scale and potentially improve its stock valuation, with a particular focus on elevating Canada's contribution to overall revenue. Analysts project strong financial performance for fiscal 2025, with expected Adjusted EBITDA of C$51.0 million on C$398.0 million in revenue, supported by a pipeline of 18 new products over the next five years.

Share Repurchase Activity

Knight Therapeutics has actively engaged in share buyback programs, including a Normal Course Issuer Bid initiated in July 2024. This program authorized the repurchase of over 5.3 million shares, with a significant portion already bought back by early 2025.

Strategic Acquisitions

The company has recently completed substantial acquisitions, such as the Paladin business and Canadian assets from Sumitomo. These deals are designed to enhance the company's market presence and revenue streams.

Ownership Trends

While no major leadership departures or new strategic investors have been prominently noted, the ongoing share buybacks and M&A activities are the primary drivers influencing Knight's ownership structure and capital allocation.

Future Outlook

The company's strategic focus on expanding its product portfolio and market reach, particularly within Canada, is expected to contribute to its financial growth. Understanding the Target Market of Knight is crucial for appreciating these strategic moves.

Knight Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔